Association between the methylenetetrahydrofolate reductase C677T polymorphism and hepatocellular carcinoma risk: a meta-analysisReportar como inadecuado




Association between the methylenetetrahydrofolate reductase C677T polymorphism and hepatocellular carcinoma risk: a meta-analysis - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Diagnostic Pathology

, 4:39

First Online: 24 November 2009Received: 18 September 2009Accepted: 24 November 2009

Abstract

BackgroundMethylenetetrahydrofolate reductase MTHFR is a key enzyme in the metabolism of folate. The non-synonymous single nucleotide polymorphism nsSNP, C677T Ala>Val, rs1801133, has been verified to impair enzyme activity. The association with cancer susceptibility, including hepatocellular carcinoma HCC, has also been widely studied. The results, however, were inconsistent. To shed light on the influence of MTHFR C677T polymorphism on HCC, a meta-analysis was conducted.

MethodsThe meta-analysis of C677T consisted of 10 studies 1814 cases-2862 controls. The association was measured by using random-effect RE or fixed-effect FE odds ratio OR combined with 95% confidence intervals CIs according to the studies- heterogeneity.

ResultsUsing genetic model analysis, C677T polymorphism was found to increase the risk of HCC in a complete overdominant model, which indicates that heterozygotes CT are at a lesser risk of HCC than either homozygotes CC or TT. Meta-analyses of the 10 studies showed that the TT genotype increased the risk of HCC as compared to the CT genotype: FE OR was 1.20 95%CI: 1.00-1.45, p for heterogeneity = 0.21. When subgroup analysis was done between the HCC cases and the chronic liver disease CLD patients of four studies, meta-analysis showed that individuals with the TT genotype had increased HCC risk compared with those with the CT genotype: FE OR TT vs. CT reached 1.81 1.22-2.71, p for heterogeneity = 0.25. Meanwhile, the C677T polymorphism also increased HCC risk in a recessive model when cases were compared to CLD patients of four studies: RE OR reached 1.85 95%CI: 1.00-3.42, p for heterogeneity = 0.06. Overall, there was some extent heterogeneity when analyses were performed in various models. There was no publication bias.

ConclusionMTHFR C677T polymorphism increased the risk of HCC in an overdominant model, and might be a risk factor for HCC occurrence, especially in CLD patients. The association warranted further studies.

AbbreviationsMTHFRmethylenetetrahydrofolate reductase

HCChepatocellular carcinoma

SNPsingle nucleotide polymorphism

ORodds ratio

CIconfidence interval.

Electronic supplementary materialThe online version of this article doi:10.1186-1746-1596-4-39 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Autor: Fei Jin - Li-Shuai Qu - Xi-Zhong Shen

Fuente: https://link.springer.com/







Documentos relacionados